ANN: PPE Giant - Gloves Off in the Commoditisation Fight
Ansell trades at $31.83 vs fair value $25.40 (-20% overvalued). Strong healthcare franchise faces examination glove commoditisation pressure with 55% thesis failure probability.
View noteAnsell trades at $31.83 vs fair value $25.40 (-20% overvalued). Strong healthcare franchise faces examination glove commoditisation pressure with 55% thesis failure probability.
View noteAustin Engineering trades at 2.7x EBITDA vs sector 9.5x median. Fair value $0.78 vs current $0.30 reflects Chilean operational recovery potential and working capital normalisation.
View noteAMP trades at $1.63 vs $1.93 fair value following successful transformation to retirement specialist. 18% upside with 4.9% yield and wide moat characteristics.
View noteGlobal packaging leader trading at $12.14 vs fair value $5.08. Quality deteriorating (5.5/10), leverage concerning (3.1x), margins unsustainable (14.4%).
View noteAtlas Arteria trades at A$49.20 versus A$87.49 fair value, offering 75% upside through regulatory normalisation catalysts with 4.9% yield and 98% FCF conversion.
View noteALS Limited trades at 16.0x EV/EBITDA (25% peer premium) despite 7.35/10 quality score. Fair value $16.77 vs current $19.78 implies 15.2% downside with mining cycle risks.
View noteTrading at $68.84 vs fair value $79.44 (15.4% upside). Gaming Operations market leader (42% share) with Interactive division scaling toward $1bn revenue by FY29. ROIC 19.2% vs WACC 10.3%.
View noteMarket leader with 27% share faces 78% downside to DCF fair value of $6.42 as energy transition accelerates, EG integration challenges emerge, and peak 4.2% EBITDA margins compress toward 3.4% terminal levels.
View noteAVOID rating with -$0.40 USD fair value vs $7.02 AUD current price. Business quality 3.1/10, negative EBITDA margins, 78% failure probability.
View noteFair value $14.96 vs current $9.76. Market leader executing renewable transformation with 9.6GW pipeline. EBITDA margins expanding 13.2% to 17.7%.
View noteDeep value opportunity trading at A$1.01 vs A$3.13 fair value. HHR network dominance with 10,496 units, pending Novomatic acquisition catalyst.
View noteStrong Sell rating with fair value -$1.64 vs current $2.69. Manufacturing segment destroys $3bn in capital whilst generating negative returns.
View note